Early Detection in Pediatric Oncology: Saving Young Lives

Stolojanu Doros^*
*Correspondence: Stolojanu Doros, Department of Pediatrics, “Victor Babes”, University of Medicine and Pharmacy, 300041 Timisoara, Romania, Email:

Introduction

Pediatric oncology is a specialized branch of medicine that deals with the diagnosis and treatment of cancer in children. The challenges it poses are immense, as cancer in children is not only rare but also distinct from the cancers that typically affect adults. Despite advancements in treatment and survival rates, the key to reducing the impact of pediatric cancer lies in early detection. Early detection can improve prognosis, reduce the intensity of treatment required, and enhance the overall quality of life for pediatric cancer survivors. This manuscript explores the importance of early detection in pediatric oncology, the methods available for detecting cancers in children, and the potential for future advancements in this field.

Description

Cancer is a leading cause of death in children worldwide, and although survival rates have improved significantly over the past few decades, the outcomes are still not guaranteed. In the United States alone, cancer is the second leading cause of death in children, following accidents. Approximately 15,000 children and adolescents are diagnosed with cancer annually, and most childhood cancers are diagnosed in children under the age of 15. The fiveyear survival rate for pediatric cancers has risen from about 50% in the 1970s to approximately 80% today, thanks to advances in cancer treatments such as chemotherapy, radiation therapy, and immunotherapy. However, survival rates vary widely depending on the type of cancer, the stage at diagnosis, and the age of the child at the time of diagnosis. For many childhood cancers, particularly those that are diagnosed at later stages, the prognosis remains grim. This makes the role of early detection even more critical, as early intervention can drastically improve outcomes [1].

Early detection in pediatric oncology is pivotal because the cancer in children often behaves differently than in adults. Childhood cancers tend to be aggressive and can progress rapidly, which means that time is often of the essence. Tumors in children may be difficult to detect at early stages due to the absence of clear symptoms or because they mimic common childhood ailments. Many children are diagnosed with cancer only after experiencing persistent symptoms that have not responded to conventional treatments, which often results in a more advanced stage of disease by the time a diagnosis is made. In such cases, the chance of successful treatment and long-term survival is significantly reduced. The earlier cancer is detected, the better the chances of effective treatment and survival. Early detection can lead to the identification of smaller, less advanced tumors, which can often be treated with less invasive methods, reducing the risk of long-term side effects [2,3].

Furthermore, early treatment can prevent the spread of cancer to other parts of the body, which is a significant concern with pediatric cancers such as leukemia, neuroblastoma, and brain tumors. There are several methods used for early detection of pediatric cancers, and the choice of method depends on the type of cancer, the child’s age, and their overall health. For some cancers, such as leukemia and lymphoma, there are specific symptoms that might prompt physicians to order blood tests and imaging studies, which can identify abnormal cell growth. For others, like brain tumors or solid tumors, early signs might include unexplained headaches, vomiting, or a noticeable mass. However, many of these symptoms can also be associated with more common, non-cancerous conditions, making it difficult to identify cancer at the outset. In some cases, parents may notice behavioural changes or developmental delays in their children, which can sometimes point to an underlying medical issue such as cancer, prompting earlier consultation with a healthcare provider [4,5].

Genetic screening and family history also play a significant role in the early detection of pediatric cancer. Certain inherited genetic mutations, such as those found in children with neurofibromatosis or retinoblastoma may increase the likelihood of developing certain types of cancer. Family members with a history of cancer can sometimes provide important clues that can lead to more intensive monitoring and earlier detection in children who might be at higher risk. However, genetic testing and screenings remain a complex issue in pediatric oncology, as they raise ethical considerations, especially regarding how much genetic information should be provided and at what age screenings should begin.

Imaging techniques such as ultrasound, CT scans, MRIs, and PET scans are also used in the early detection of cancer in children. These technologies have advanced considerably, making it easier to detect tumors and other signs of cancer in the body. MRIs, for example, provide highly detailed images of the brain and spinal cord, which are commonly affected by childhood cancers like medulloblastoma and gliomas. Ultrasound, while less invasive, is often used to detect abdominal tumors or assess changes in organs such as the kidneys or liver. However, these imaging techniques are not always perfect, and small tumors may still be missed, particularly if they are located in difficult-to-image areas.

In addition to imaging, blood tests are increasingly used in the early detection of pediatric cancers. For example, blood tests that detect specific markers in the blood can help identify certain cancers at an earlier stage. Tumor markers like Alpha-Fetoprotein (AFP) and Human Chorionic Gonadotropin (HCG) are associated with certain types of cancers, such as testicular cancer and germ cell tumors. Other biomarkers are being studied for their ability to detect cancers like leukemia or brain tumors in children. Liquid biopsy, a relatively new approach, is also showing promise in detecting cancer by analysing the DNA or RNA fragments released by tumor cells into the bloodstream. While still in the experimental stages, liquid biopsy could eventually become a standard method for early cancer detection, offering a non-invasive, cost-effective alternative to current diagnostic procedures.

Conclusion

Early detection in pediatric oncology is an essential tool in saving young lives. The earlier a cancer is detected, the greater the chances of successful treatment and long-term survival. Although there are several challenges to early detection, including the rarity of childhood cancers, the lack of universal screening guidelines, and the difficulty of detecting tumors at early stages, ongoing advancements in technology and research are improving our ability to detect cancer in children earlier and more accurately. As more progress is made in early detection methods, we can expect to see better outcomes for children with cancer, ultimately saving more young lives and improving the quality of life for pediatric cancer survivors. However, continued investment in research, education, and the development of screening protocols is crucial to ensuring that all children, regardless of their background or geographic location, have the best possible chance of surviving cancer.

Acknowledgement

None.

Conflict of Interest

No potential conflict of interest was reported by the authors.

References

1. Zahnreich, Sebastian and Heinz Schmidberger. "Childhood cancer: Occurrence, treatment and risk of second primary malignancies." Cancers 13 (2021): 2607.

Google Scholar, Crossref, Indexed at

2. Mancilla, Trevi R., Brian Iskra and Gregory J. Aune. "Doxorubicin-induced cardiomyopathy in children." Compr Physiol 9 (2019): 905.

Google Scholar, Crossref, Indexed at

3. Hitawala, Gazala, Esha Jain, Lisett Castellanos and Radhika Garimella, et al. "Pediatric chemotherapy drugs associated with cardiotoxicity." Cureus 13, no. 11 (2021).

Google Scholar, Crossref, Indexed at

4. Harake, Danielle, Vivian I. Franco, Jacqueline M. Henkel and Tracie L. Miller, et al. "Cardiotoxicity in childhood cancer survivors: Strategies for prevention and management." Future Cardiol 8 (2012): 647-670.

Google Scholar, Crossref, Indexed at

5. Lipshultz, Steven E., Ruchika Karnik, Peter Sambatakos and Vivian I. Franco, et al. "Anthracycline-related cardiotoxicity in childhood cancer survivors." Curr Opin Cardiol 29 (2014): 103-112.

Google Scholar, Crossref, Indexed at